Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

@article{Neubauer2008PatientsWA,
  title={Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.},
  author={Andreas Neubauer and Kati S. Maharry and Krzysztof Mr{\'o}zek and Christian Thiede and Guido Marcucci and Peter Paschka and Robert J. Mayer and Richard A Larson and Edison T. Liu and Clara D. Bloomfield},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 28},
  pages={4603-9}
}
PURPOSE RAS mutations occur in 12% to 27% of patients with acute myeloid leukemia (AML) and enhance sensitivity to cytarabine in vitro. We examined whether RAS mutations impact response to cytarabine in vivo. PATIENTS AND METHODS One hundred eighty-five patients with AML achieving complete remission on Cancer and Leukemia Group B study 8525 and randomly assigned to one of three doses of cytarabine postremission were screened for RAS mutations. We assessed the impact of cytarabine dose on… CONTINUE READING